Genmab — Januar 2016
-
Jeg er med på, at ingen regner med noget, men det forekommer mig alligevel, at CLL maintenance godkendelse bliver lidt undervurderet. For eksempel er Lenalidomide for tiden i fase III for det samme. I et ASCO abstract skriver de: Despite recent advances in chemo-immunotherapy combinations for the treatment (Tx) of CLL, most patients (pts) relapse and eventually die from the disease. Maintenance therapy has made impact in other B-cell cancers, such as myeloma; its role and the optimal agent in CL
-
Jeg tillægger det ikke den store værdi før vi ser Genmab/Novartis omtale det mulige marked - eller vi ganske enkelt begynder at se et reelt uptake. Jan har dog tidligere været ret positiv på netop denne indikation, men synes ikke det forholder sig sådan længere.
-
-
Endnu en dag i "galeanstalten". Gad vide, hvornår fornuften atter råder? http://jyskebank.tv/014528558931057/seniorstrategen-markedet-overreagerer
-
fra jannsen webcast 15 januar. lyt fra 9 minutter inde i webcastet til 9.40. i mine øre lyder det snart som read out data, eller hvad ? http://edge.media-server.com/m/p/a7xtit7p
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind

